Ahmadshah Mirkhel, MD
Nephrology · Fairfax, VANPI 1790729317
Payments from drug & device makers
Across 195 payments — averaging $4624.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$685K
- Bayer$121K
- CSL Behring$42K
- Hoffmann-la Roche Limited$35K
- Biogen$16K
- AstraZeneca$261
- plus $2K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 29 | $684,521 |
| Bayer | 44 | $120,856 |
| CSL Behring | 23 | $42,364 |
| Hoffmann-la Roche Limited | 12 | $35,418 |
| Biogen | 2 | $16,439 |
| AstraZeneca(2 entities) | 13 | $261 |
| Akebia Therapeutics Inc | 8 | $249 |
| Mallinckrodt Hospital Products Inc. | 7 | $188 |
| Ardelyx, Inc. | 6 | $163 |
| Amgen(2 entities) | 7 | $160 |
| Otsuka America Pharmaceutical, Inc. | 4 | $147 |
| ANI Pharmaceuticals, Inc. | 4 | $113 |
| Calliditas Therapeutics US Inc. | 2 | $101 |
| Travere Therapeutics, Inc. | 6 | $93 |
| GSK | 3 | $80 |
| Aurinia Pharma U.S., Inc. | 3 | $78 |
| Fresenius USA Marketing, Inc. | 4 | $66 |
| OPKO Pharmaceuticals, LLC | 3 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Mallinckrodt Enterprises LLC | 1 | $49 |
| Lilly USA, LLC | 2 | $47 |
| Vifor Pharma, Inc. | 2 | $37 |
| Cormedix Inc. | 1 | $30 |
| Genentech USA, Inc. | 1 | $25 |
| Recor Medical Inc | 1 | $22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Biomerieux Inc | 1 | $12 |
How this compares
$901,681 in reported general payments places this provider in the 95th percentile of 298 nephrology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Fairfax
- Renuka SothinathanFairfax$617K
- Reza ZonoziFairfax$482K
- Ali AssefiFairfax$302K
- Kinjal PatelFairfax$31K
- Gregory WangFairfax$30K
- Renu Regunathan-ShenkFairfax$22K
- Paul ModlingerFairfax$18K
- Magnus IkhinmwinFairfax$11K
- Olayiwola AyodejiHampton$7M
- Kiranjit DhillonNorfolk$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.